How to Distinguish Patients with pSS among Individuals with Dryness without Invasive Diagnostic Studies

Table 2

Detailed distribution of anti-SSA, anti-SSB, and anti-Ro52 specific antibodies and their titers (luminous intensity 0–3) in pSS patients.

Anti-SSA—number of patients/%	Anti-SSB—number of patients/%	Anti-Ro52—number of patients/%
Titer 3+—54 patients/79%	Titer 3+—37 patients/54%	Titer 3+—44 patients/65%
Titer 2+—one patient	Titer 2+—6 patients/9%	Titer 2+—0 patients
Titer 1+—one patient	Titer 1+—3 patients	Titer 1+—3 patients
	Titer 0.5+—one patient	Titer 0.5+—one patient
Only anti-SSA—0 patients	Only anti-SSB—0 patients	Only anti-Ro52—3 patients/4%
anti-SSA + SSB—10 patients/15%	anti-SSA + SSB—10 patients/15%	anti-SSA + Ro52—9 patients/13%
anti-SSA + Ro52—9 patients/13%	anti-SSB + Ro52—0 patients	anti-SSB + Ro52—0 patients
anti-SSA + SSB + Ro52—37 patients/54%	anti-SSA + SSB + Ro52—37 patients/54%	anti-SSA + SSB + Ro52—37 patients/54%

For ANA testing, the EUROIMMUN Hep-20-10/liver monkey set was used. For determination of antigen specificity of the anti-nuclear antibodies, Anti-Ena Profile Plus 1 Euroline immunoblotting set was used.